MESO News

As we noted in a mid-week blog post, AAAP had the best first-day pop (+53%) for an IPO in three months, and on the same day Voyager had the best pop in almost two months (+27%). While there were no biotech filings this past week, it is a safe...read more

Mesoblast, which is developing regenerative medicine based on adult stem cells, raised $60 million by offering 7.5 million ADSs at $8, well below the expected $12.10 price. Mesoblast plans to list on the Nasdaq under the symbol MESO. J.P. Morgan and Credit Suisse acted as lead managers on the deal....read more

The IPO market is having its pre-Thanksgiving feast. Nine companies are on the IPO calendar to raise a combined $1.0 billion during the week ahead. Online mortgage company loanDepot and education software provider Instructure stand out. The IPO market could see four mid-large companies in the biotech space,...read more

November has kicked off with seven new additions to the IPO calendar, including four health care deals, two financial firms and one software provider. The next seven days should see even more companies launch roadshows in order to begin trading before Thanksgiving. The calendar filled up as both the...read more